STUDY PROTOCOL

What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic review [version 1; peer review: awaiting peer review]

Melina Michelen1, Louise Sigfrid2, Lakshmi Manoharan2, Natalie Elkeir10,2,3, Claire Hastie4, Margaret O'Hara4, Jake C. Suett4,5, Vincent Cheng6, Amanda Burls1, Carol Foote7, Charitini Stavropoulou10

1School of Health Sciences, City, University of London, London, UK
2ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
3Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
4Long Covid Support, Birmingham, UK
5Queen Elizabeth Hospital Kings Lynn, Norfolk, UK
6Bristol Medical School, University of Bristol, Bristol, UK
7Independent Editor, Soquel, California, USA

V1 First published: 14 Dec 2020, 9:1455
https://doi.org/10.12688/f1000research.27284.1
Latest published: 14 Dec 2020, 9:1455
https://doi.org/10.12688/f1000research.27284.1

Abstract

Although the majority of patients with COVID-19 will experience mild to moderate symptoms and will recover fully, there is now increasing evidence that a significant proportion will experience persistent symptoms for weeks or months after the acute phase of the illness. These symptoms include, among others, fatigue, problems in breathing, lack of smell and taste, headaches, and also depression and anxiety. It has also become clear that the virus has lasting effects not only on the respiratory system but also on other parts of the body, including the heart, liver, and the nervous system. In this paper we present a protocol for a living systematic review that aims to synthesize the evidence on the prevalence and duration of symptoms and clinical features of post-acute COVID-19 and its long-term complications. The living systematic review will be updated regularly, initially monthly with update cycles under continuous review as the pace of new evidence generated develops through the pandemic. We will include studies that follow up with COVID-19 patients who have experienced persistent mild, moderate or severe symptoms, with no restrictions regarding country, setting, or language. We will use descriptive statistics to analyse the data and our findings will be presented as infographics to facilitate transcription to lay audiences. Ultimately, we aim to support the work of policy makers,
practitioners, and patients when planning rehabilitation for those recovering from COVID-19. The protocol has been registered with PROSPERO (CRD42020211131, 25/09/2020).

**Keywords**
Living systematic review, COVID-19, long covid, lasting effects

This article is included in the Disease Outbreaks gateway.

This article is included in the Coronavirus collection.

**Corresponding author:** Charitini Stavropoulou (C.Stavropoulou@city.ac.uk)

**Author roles:**
- Michelen M: Data Curation, Formal Analysis, Investigation, Methodology, Validation, Writing – Review & Editing; Sigfrid L: Funding Acquisition, Methodology, Validation, Writing – Review & Editing; Manoharan L: Data Curation, Formal Analysis, Methodology, Validation, Writing – Review & Editing; Elkheir N: Data Curation, Investigation, Methodology, Validation, Writing – Review & Editing; Hastie C: Investigation, Validation, Writing – Review & Editing; O’Hara M: Investigation, Validation, Writing – Review & Editing; Suett JC: Investigation, Methodology, Validation, Writing – Review & Editing; Cheng V: Data Curation, Formal Analysis, Investigation, Methodology, Validation, Writing – Review & Editing; Burls A: Investigation, Validation, Writing – Review & Editing; Foote C: Investigation, Validation, Writing – Review & Editing; Stavropoulou C: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work was supported by the Department for International Development and Wellcome [215091] and the Bill and Melinda Gates Foundation [OPP1209135].

**Copyright:** © 2020 Michelen M et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Michelen M, Sigfrid L, Manoharan L et al. What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic review [version 1; peer review: awaiting peer review] F1000Research 2020, 9:1455 https://doi.org/10.12688/f1000research.27284.1

**First published:** 14 Dec 2020, 9:1455 https://doi.org/10.12688/f1000research.27284.1
Background
More than six months into the pandemic, our knowledge around COVID-19 continues to develop rapidly. The range of documented COVID-19 infections vary from asymptomatic to severe, but the vast majority of patients experience mild to moderate symptoms and do not require hospitalisation. We have previously conducted a rapid review of the literature to identify which symptoms and signs might differentiate mild and moderate from severe COVID-19. Since then, and as more data are being gathered, there is increasing evidence of a “long-tail” of COVID-19 illness, but limited information about the range and duration of symptoms experienced or longer term health complications. A community app developed at King’s College London, which tracks self-reported symptoms, has shown that about one in ten will be sick for three weeks or more (https://covid.joinzoe.com/post/covid-long-term). Some individuals with COVID-19 have reported fatigue, headaches and tingling nerves that lasted months after symptom onset. A recent longitudinal cohort of 143 patients followed after hospitalisation from COVID-19 in Italy reported that 87% had at least one ongoing symptom, most (55%) reporting three or more, at 60 day follow up. Fatigue (53%), dyspnoea (43%), joint pain (27%) and chest pain (22%) were the most common ongoing symptoms, but there is a variety of other symptoms and complications that have been reported including neurocognitive difficulties, muscle pains and weakness, gastrointestinal upset, rashes, metabolic disruption, thromboembolic conditions and mental health conditions. A prolonged course of illness has also been reported among people with mild COVID-19 who did not require hospitalisation.

The evidence to date remains fragmented as to the onset of symptoms and clinical features, how long symptoms may last, how this relates to the severity of the initial illness, and further lasting impacts to health. A better understanding of patients’ projected recovery from COVID-19 is helpful to patients, healthcare professionals, policymakers and commissioners. The clinical management of persisting symptoms of COVID-19 has started to be addressed in the clinical literature and NHS England has issued guidance for the multisystem needs of patients recovering from COVID-19. Our findings could help identify people requiring additional rehabilitation services and, where necessary, specialist referral to establish a secondary cause of their symptoms. Our findings will also be relevant to organisations such as NHS England, which have recently launched an online COVID-19 rehab service supporting patients suffering long-term effects of the disease (https://www.your-covidrecovery.nhs.uk/) or the British Society of Immunologists, which recently released a briefing note recommending research into the long-term immunological health consequences of COVID-19.

The aim of this review is to synthesize the evidence on the prevalence and duration of symptoms and clinical features of post-acute COVID-19 and its long-term complications. This will inform clinical and public health management, prevention and rehabilitation policies.

Methods
To address the aim of this study we will conduct a living systematic review (LSR). LSRs are used in areas where research evidence is emerging rapidly, current evidence is uncertain, and new research may influence policy or practice decisions. These are all features of COVID-19 research, where much about the long-term effects of the disease are still unknown and policy makers are calling for more evidence. The review will be initially updated monthly, with update cycles under continuous review as the pace of new evidence generated develops through the pandemic. We aim to continue to update the review for up to two years. Our study methodology has been developed and strengthened through consultation with Long Covid Support (a patient support network).

Inclusion/exclusion criteria
We will include studies that meet the follow criteria:

- Studies of patients with COVID-19 who have persistent mild, moderate or severe symptoms as defined by the article authors
- Studies following up with COVID-19 patients
- Peer reviewed articles published since 1st January 2020
- No restriction regarding country, setting or language

We will exclude:
- Studies that focus only on acute COVID-19
- Editorials and opinion papers

Search strategy
A search of the following databases will be conducted: Pubmed and CINAHL through the EBSCO database host for general health peer-reviewed articles and Global Health for global peer-reviewed articles through the Ovid database host. In addition, we will search Cochrane for relevant systematic reviews and Google Scholar for grey literature including pre-prints. We will also look at the WHO Global Research Database on COVID-19 and LitCOVID as two databases that bring together evidence on COVID-19 from a worldwide dataset. Finally, we will contact experts in the field and use social media to identify relevant studies.

Data will be managed using the review software Rayyan.

Key search terms
We will search using controlled subject headings and keywords of the following concepts: Terms related to 1) COVID-19 OR COVID OR SARS-CoV-2; 2) symptoms OR clinical features OR signs OR characteristics OR sequelae OR complications; 3) long-term OR post-acute OR long-tail OR persistent OR chronic COVID OR long COVID OR post discharge OR prolonged symptoms OR long haul. The search terms were piloted on Pubmed and CINAHL through the EBSCO database host the week starting 14th September 2020 to ensure that
recent high profile research articles on long covid were included. No important studies were missed.

An example is shown below:

**MEDLINE Search**

| S1. COVID-19 OR OR covid OR SARS-CoV-2. ab | 31,903 |
| S2. symptom* OR ‘clinical features’ OR signs OR characteristic* OR sequelae OR complication*.ab | 188,243 |
| S3. “long-term Covid” OR long-term N2 consequence* OR “long-term impact” OR “long-term effect” OR “post-acute” OR long-tail OR persist* OR “chronic-COVID” OR “long-COVID” OR post-discharge OR postdischarge OR “prolonged symptom” OR “long-haul”.ab | 25,598 |
| S4. S1 AND S2 AND S3 | 309 |

**Screening**

Initial screening of titles and abstracts as well as full text screening against the inclusion criteria will be done by two reviewers. Disagreements for inclusion will be resolved by consensus. Where disagreements cannot be resolved, a third reviewer will review the papers to make the final decision.

**Critical appraisal checklist**

We will be using the Hoy *et al.* checklist11 to critically appraise the studies included in the review.

**Data extraction**

The following information will be extracted from each study based on the extraction form used for our initial review12: study aim, country of study, setting, method, study design and population size and characteristics, types and frequency of symptoms reported, onset and duration of symptoms. Data extraction will be performed by one reviewer and checked by a second reviewer. Disagreements will be resolved through discussion and consensus.

**Data analysis**

We will use descriptive statistics to summarise the types of symptoms, their frequency and duration. We will perform subgroup analysis on the basis of age, sex, comorbidities and severity of the disease. The data will be presented as infographics to facilitate transcription to lay audiences.

**Protocol registration**

This protocol report is structured according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement guidelines13, was registered with PROSPERO (CRD42020211131, 25 September 2020). The protocol will be updated as we progress with the living review as and if needed. CS is the guarantor for this study.

**Data availability**

**Underlying data**

No underlying data are associated with this article.

**Reporting guidelines**

Figshare: PRISMA-P checklist for “What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic review”. https://doi.org/10.25383/city.13187456.v115.

---

**References**

1. CDC: Coronavirus Disease 2019 (COVID-19). Cent Dis Control Prev. 2020; (accessed 6 Aug 2020). Reference Source
2. Michelen M, Jones N, Stavropoulou C: In patients of COVID-19, what are the symptoms and clinical features of mild and moderate cases? (accessed 6 Aug 2020). Reference Source
3. Rayner C, Lokugamage AU, Molokhia M: Covid-19: Prolonged and relapsing course of illness has implications for returning workers. 2020; (accessed 6 Aug 2020). Reference Source
4. Garner P: Paul Garner: Covid-19 at 14 weeks—phantom speed cameras, unknown limits, and harsh penalties. The BMJ. (accessed 6 Aug 2020). Reference Source
5. Carfi A, Bernabei R, Landi F, et al: Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020; 324(6): 603–5. PubMed Abstract | Publisher Full Text | Free Full Text
6. Greenhalgh T, Knight M, A’Court C, et al: Management of post-acute covid-19 in primary care. BMJ. 2020; 370: m3026. PubMed Abstract | Publisher Full Text
7. Tenforde MW: Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 993–998. Publisher Full Text
8. Sigfrid L, Cevik M, Jesudason E, et al: What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study. medRxiv. 2020. Publisher Full Text
9. NHS England and NHS Improvement: After-care needs of inpatients recovering from COVID-19. 2020; (accessed 24 Sep 2020). Reference Source
10. British Society for Immunology: COVID-19 immunology briefing note: What we know about long-term health consequences and priorities for research. Immunology. 2020. Reference Source
11. Elliott JH, Symnot A, Turner T, et al: Living systematic review: 1. Introduction—the why, what, when, and how. J Clin Epidemiol. 2017; 81: 23–30. PubMed Abstract | Publisher Full Text
12. Ouzzani M, Hammady H, Fedorowicz Z, et al: Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016; 5(1): 210. PubMed Abstract | Publisher Full Text | Free Full Text
13. Hoy D, Brooks P, Woolf A, et al: Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012; 65(9): 934–9. PubMed Abstract | Publisher Full Text
14. Moher D, Shamseer L, Clarke M, et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4(1): 1. PubMed Abstract | Publisher Full Text | Free Full Text
15. Michelen M, Sigfrid L, Manoharan L, et al: What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic review. City, University of London. Journal contribution. 2020. http://www.doi.org/10.25383/city.13187456.v1
The benefits of publishing with F1000Research:

• Your article is published within days, with no editorial bias
• You can publish traditional articles, null/negative results, case reports, data notes and more
• The peer review process is transparent and collaborative
• Your article is indexed in PubMed after passing peer review
• Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com